Powerful & Fast
BioAtla’s proprietary CPE and CPS processes are the fastest, most comprehensive in vivo evolution technologies available today. These technologies are capable of generating antibodies with sub-picomolar binding affinity, humanized antibodies and proteins with improved pharmacokinetics and enhanced stability. The high through-put capabilities of BioAtla’s technologies are best illustrated by the antibody humanization program which requires less than 3 months to complete humanization of a full-length antibody molecule by screening in mammalian cells, achieving binding affinities equivalent or superior to the native antibody binding affinities.